ARRIVENT BIOPHARMA, INC. Operating Cash Flow
ARRIVENT BIOPHARMA, INC. (AVBP) reported Operating Cash Flow of -$81.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$39.58M.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$41.89M.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$30.66M.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$35.80M.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$160.59M.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$70.21M.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$55.84M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$81.47M 10-Q · filed 2026-08-12 | -$112.13M derived: sum of 3 quarters · filed 2026-08-12 | -$147.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$41.89M 10-Q · filed 2026-05-11 | -$72.55M derived: sum of 2 quarters · filed 2026-05-11 | -$108.35M derived: sum of 3 quarters · filed 2026-05-11 | -$134.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$30.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$66.46M derived: sum of 2 quarters · filed 2026-03-05 | -$92.58M derived: sum of 3 quarters · filed 2026-08-12 | -$160.59M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$35.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$61.92M derived: sum of 2 quarters · filed 2026-08-12 | -$129.93M 10-Q · filed 2025-11-10 | -$146.08M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$26.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$94.13M 10-Q · filed 2026-08-12 | -$110.28M derived: sum of 3 quarters · filed 2026-08-12 | -$126.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$68.01M 10-Q · filed 2026-05-11 | -$84.16M derived: sum of 2 quarters · filed 2026-05-11 | -$100.50M derived: sum of 3 quarters · filed 2026-05-11 | -$119.59M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$16.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$32.50M derived: sum of 2 quarters · filed 2026-03-05 | -$51.58M derived: sum of 3 quarters · filed 2026-03-05 | -$70.21M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$16.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$35.43M derived: sum of 2 quarters · filed 2025-11-10 | -$54.06M 10-Q · filed 2025-11-10 | -$68.97M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$19.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$37.72M 10-Q · filed 2025-08-11 | -$52.63M derived: sum of 3 quarters · filed 2025-08-11 | -$68.07M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$18.63M 10-Q · filed 2025-05-12 | -$33.54M derived: sum of 2 quarters · filed 2025-05-12 | -$48.98M derived: sum of 3 quarters · filed 2025-05-12 | -$57.59M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$14.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$30.36M derived: sum of 2 quarters · filed 2025-03-03 | -$38.96M derived: sum of 3 quarters · filed 2025-03-03 | -$55.84M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$15.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$24.05M derived: sum of 2 quarters · filed 2024-11-14 | -$40.93M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$8.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$25.49M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$16.88M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |